Carlsmed vs CVRx
CVRx reported revenue of $57 million in fiscal 2025, about the same as Carlsmed's $50 million in fiscal 2025. Carlsmed's revenue grew 85.9% in its latest year, and CVRx's grew 10.4%. Carlsmed had an operating margin of -60.5%, against -90.5% at CVRx. Free cash flow was −$30 million at Carlsmed and −$41 million at CVRx.
Side by side
| Carlsmed | CVRx | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $50M | $57M |
| Revenue growth | 85.9% | 10.4% |
| Revenue growth a year, last 5 years | — | 56.2% |
| Gross margin | 75.3% | 85.3% |
| Operating margin | −60.5% | −90.5% |
| Net margin | −58.7% | −94.1% |
| Free cash flow | −$30M | −$41M |
| Free cash flow margin | −58.6% | −71.9% |
| Return on capital | — | −294.3% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 249.7% | 15.4% |
| Last close | $17.22 | $0.53 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $2.6 million | bought $376,741, sold $220,566 |
| Piotroski F-score | — | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CarlsmedCVRx
Operating margin
Percent of revenue
CarlsmedCVRx
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CarlsmedCVRx